Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Retained Earnings: 2019-2024

Historic Retained Earnings for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to -$474.0 million.

  • Silence Therapeutics' Retained Earnings fell 22.29% to -$550.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$550.8 million, marking a year-over-year decrease of 22.29%. This contributed to the annual value of -$474.0 million for FY2024, which is 9.76% down from last year.
  • Silence Therapeutics' Retained Earnings amounted to -$474.0 million in FY2024, which was down 9.76% from -$431.9 million recorded in FY2023.
  • Silence Therapeutics' Retained Earnings' 5-year high stood at -$236.6 million during FY2020, with a 5-year trough of -$474.0 million in FY2024.
  • Its 3-year average for Retained Earnings is -$410.6 million, with a median of -$431.9 million in 2023.
  • Data for Silence Therapeutics' Retained Earnings shows a maximum YoY plummeted of 32.56% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Silence Therapeutics' Retained Earnings stood at -$236.6 million in 2020, then fell by 29.68% to -$306.8 million in 2021, then decreased by 6.21% to -$325.8 million in 2022, then crashed by 32.56% to -$431.9 million in 2023, then declined by 9.76% to -$474.0 million in 2024.